Bausch Health Companies Inc.BHC

Bausch Health Companies Inc. reported a net loss of $1.42 billion for the period ending 31 March 2026, according to its 10-Q filing with the SEC. Revenue from contracts with customers reached $2.52 billion, but operating loss was $950 million and diluted earnings per share came in at negative $3.82. The company's total assets stood at $24.50 billion against total liabilities of $25.58 billion, leaving stockholders' equity attributable to the parent at a deficit of $2.06 billion.

Bausch Health operates across gastroenterology, hepatology, neuroscience, dermatology, dentistry and international pharmaceuticals. The Salix segment relies heavily on the Xifaxia product line, which the 10-Q filing states represents approximately 85 per cent of that segment's revenues. The company also runs a patient assistance programme for Medicaid patients whose plans no longer cover its products, and its OraPharma unit develops oral health treatments for conditions including adult periodontitis and mouth dryness.

Cash and cash equivalents were $1.30 billion at the end of the period, while net cash provided by operating activities was $230 million. Payments to acquire property, plant and equipment totalled $109 million. Inventory, net, stood at $1.60 billion, with an increase in inventories of $14 million during the period. The weighted average diluted share count was 372.8 million shares.

The evidence supplied today does not include a share price chart or trading range, so no price context can be drawn from the source rail. The filing facts and product descriptions are the primary market evidence for the current date. The heavy reliance on the Xifaxia franchise within the Salix segment is a concentrated revenue risk, while the international segment sells branded pharmaceuticals, branded generics and OTC products outside the United States, except for Bausch + Lomb products and Solta Medical aesthetic devices.

Between 2 July and 20 July 2026, the company filed multiple Form 4 ownership reports with the SEC, indicating changes in insider holdings. The filings do not detail the nature of the transactions beyond the regulatory requirement, but they arrive during a period when the company's balance sheet shows negative equity and substantial liabilities. The product rail from Bausch Health's own website confirms a diversified portfolio, yet the 10-Q numbers show that diversification has not yet translated into positive net worth. What remains unproven is whether the company can convert its product breadth and operating cash generation into a balance sheet recovery, and any future filing that shows a reduction in liabilities or a return to positive equity would be a material change worth examining.